{"paper_id": "acbcac3aeb5c5275f611cc2fe5ed1f8650268f72", "metadata": {"title": "Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19 Online appendix Charlson Comorbidity Indices ..................................................................................................3 Falsification Endpoints..............................................................................................................4 eTable 2: Drug Classes & Generic Names ..................................................................... 5 Antihypertensive Drugs ............................................................................................................5 Additional drug classes of interest ..........................................................................................6 eTable 3. Falsification endpoint for outpatient and inpatient cohorts after matching ............................................................................................................................. 7 eTable 4: Secondary outcome of in-hospital mortality in the outpatient cohort of SARS-CoV-2 positive patients ......................................................................................... 8 eTable 5: Length of Stay (Median, IQR) for COVID-19 Inpatients after propensity score matching ................................................................................................................ 10 eTable 6: Hazard ratio for Hospitalization among Individuals Testing Positive for SARS-CoV-2 in the Outpatient Setting, where control arm uses first-line antihypertensive drugs only. ......................................................................................... 11 eTable 7: Hazard ratio for Mortality in Hospitalized COVID-19 patients, where control arm uses first-line antihypertensive drugs only. .......................................... 12 eTable 8: Unadjusted hazard ratio for Hospitalization in outpatient SARS-CoV-2 positive patients. ............................................................................................................. 13 eFigure 1: Outpatient Cohort Selection Flowsheet .................................................... 15 eFigure 2: Inpatient Cohort Selection Flowsheet ....................................................... 16 eFigure 3: Distribution of individuals in the outpatient and inpatient cohorts. ..... 17", "authors": [{"first": "Rohan", "middle": [], "last": "Khera", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Callahan", "middle": [], "last": "Clark", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yuan", "middle": [], "last": "Lu", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "Yinglong", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Guo", "middle": [], "last": "Ma", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Sheng", "middle": [], "last": "Ren", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Brandon", "middle": [], "last": "Truax", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Erica", "middle": [], "last": "Spatz", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Mhs", "middle": [";"], "last": "Karthik", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhenqiu", "middle": [], "last": "Lin", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "Saad", "suffix": "", "affiliation": {}, "email": ""}, {"first": "B", "middle": [], "last": "Omer", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Deneen", "middle": [], "last": "Vojta", "suffix": "", "affiliation": {}, "email": ""}, {"first": "#", "middle": [";"], "last": "Harlan", "suffix": "", "affiliation": {}, "email": ""}, {"first": "M", "middle": [], "last": "Krumholz", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Sm", "middle": ["#"], "last": "", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": " Inclusion Criteria  ICD-10 Codes  Hypertension  I10%, I11%, I12%, I13%, I15%, I16%, I67 G468, I690, G462, I606, G452, I682, I613, I634, I650, I668, I662, I670, G463, I679, I673,  H340, I607, I669, G464, I692, I699, G454, I691, I620, I660, I658, I605, I635, I608, G461,  I602, I616, G458, I676, I604, I699, I621, I600, I677, I672 ", "cite_spans": [], "ref_spans": [{"start": 1, "end": 88, "text": "Inclusion Criteria  ICD-10 Codes  Hypertension  I10%, I11%, I12%, I13%, I15%, I16%, I67", "ref_id": null}, {"start": 89, "end": 329, "text": "G468, I690, G462, I606, G452, I682, I613, I634, I650, I668, I662, I670, G463, I679, I673,  H340, I607, I669, G464, I692, I699, G454, I691, I620, I660, I658, I605, I635, I608, G461,  I602, I616, G458, I676, I604, I699, I621, I600, I677, I672", "ref_id": null}], "section": ""}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "A) ACE inhibitor verses others in full population, histogram of p-values (B) ACE inhibitor verses others in the full population, histogram of hazard ratios (C) ACE inhibitor verses others in Medicare Advantage population, histogram of p-values (D) ACE inhibitor verses others in Medicare Advantage population", "authors": [], "year": null, "venue": "Histogram on p-values and adjusted hazard ratios from 100 matches", "volume": "6", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Propensity score distributions for treatment comparisons in the outpatient cohort ............................................................................................................. 18 (A) ACE inhibitor vs others ................................................................................................ 18 (B) ARB vs others ................................................................................................................ 18 eFigure 5: Propensity score distributions for treatment comparisons in the inpatient cohort ............................................................................................................... 19 (A) ACE inhibitor vs others ................................................................................................ 19(B) ARB vs others ................................................................................................................ 19 eFigure 6: Histogram on p-values and adjusted hazard ratios from 100 matches. 20 (A) ACE inhibitor verses others in full population, histogram of p-values .................. 20 (B) ACE inhibitor verses others in the full population, histogram of hazard ratios .. 20 (C) ACE inhibitor verses others in Medicare Advantage population, histogram of pvalues ........................................................................................................................................ 21 (D) ACE inhibitor verses others in Medicare Advantage population, histogram of hazard ratios ............................................................................................................................. 21 eTable 1: ICD-10 codes Inclusion Criteria", "latex": null, "type": "figure"}, "FIGREF1": {"text": "J430, J431, J432, J438, J439, J440, J441, J449, J452, J453, J454, J455, J459, J470, J471, J479, J620, J628, J630, J631, J632, J633, J634, J635, J636, J660, J661, J662, J668, J670, J671, J672, J673, J674, J676, J677, J678, J679, J684, J701, J703 Peptic Ulcer Disease K250, K282, K259, K277, K269, K256, K286, K272, K273, K285, K253, K270, K280, K275, K266, K281, K276, K274, K283, K287, K252, K251, K257, K260, K284, K289, K254, K263, K261, K267, K262, K264, K259, K271, K265, M315, M320, M321, M322, M323, M325, M328, M329, M330, M331, M332, M333, M334, M335, M336, M339, M340, M341, M342, M343, M344, M345, M346, M348, M349, M353, M360 Hemiplegia and Paraplegia G114, G801, G802, G810, G811, G818, G819, G820, G821, G822, G825, G828, G829, G830, G831, G832", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Propensity score distributions for treatment comparisons in the outpatient cohort (A) ACE inhibitor vs others (B) ARB vs others (C) ACE inhibitor vs ARB eFigure 5: Propensity score distributions for treatment comparisons in the inpatient cohort (A) ACE inhibitor vs others (B) ARB vs others (C) ACE inhibitor vs ARB", "latex": null, "type": "figure"}, "TABREF2": {"text": "Benazepril/hydrochlorothiazide, Benazepril hcl, Captopril, Captopril/hydrochlorothiazide, Enalapril/hydrochlorothiazide, Enalapril maleate, Fosinopril/hydrochlorothiazide, Fosinopril sodium, Lisinopril, Lisinopril/hydrochlorothiazide, moexipril/hydrochlorothiazide, Moexipril hcl, Perindopril arg/amlodipine bes, Perindopril erbumine, Quinapril/hydrochlorothiazide, Quinapril hcl, Ramipril, Trandolapril, Trandolapril/verapamil hcl Angiotensin II receptor antagonists Azilsartan med/chlorthalidone, Azilsartan medoxomil, Candesartan/hydrochlorothiazid, Candesartan cilexetil, Eprosartan mesylate, Irbesartan, Irbesartan/hydrochlorothiazide, Losartan/hydrochlorothiazide, Losartan potassium, Olmesartan/amlodipin/hcthiazid, Olmesartan/hydrochlorothiazide, Olmesartan, medoxomil, Sacubitril/valsartan, Telmisartan, Telmisartan/amlodipine, Telmisartan/hydrochlorothiazid, Valsartan, Valsartan/hydrochlorothiazide Beta-adrenergic blocking agents Acebutolol hcl, Atenolol, Atenolol/chlorthalidone, Betaxolol hcl Bisoprolol/hydrochlorothiazide, Bisoprolol fumarate, Bisoprolol fumarate/hctz, Amlodipine benzoate, Amlodipine besylate, Amlodipine besylate/valsartan, Amlodipine/valsartan/hcthiazid, Amlodipine es/olmesartan med, Amlodipine besylate/benazepril Felodipine, Isradipine, Nifedipine, Nisoldipine, olmesartan/amlodipin/hcthiazid, telmisartan/amlodipine Calcium-channel blocking agents, non-dihydropyridine Amiloride/hydrochlorothiazide , Amlodipine/valsartan/hcthiazid, Azilsartan med/chlorthalidone, Benazepril/hydrochlorothiazide, Bisoprolol/hydrochlorothiazide, Bisoprolol fumarate/hctz, Candesartan/hydrochlorothiazide, Captopril/hydrochlorothiazide, Clonidine hcl/chlorthalidone, Chlorothiazide, Hydrochlorothiazide, Chlorthalidone, Enalapril/hydrochlorothiazide, Fosinopril/hydrochlorothiazide, Indapamide, Irbesartan/hydrochlorothiazide, Lisinopril/hydrochlorothiazide, Losartan/hydrochlorothiazide, Methyldopa/hydrochlorothiazide, Metolazone, Metoprolol/hydrochlorothiazide, Metoprolol su/hydrochlorothiaz, Moexipril/hydrochlorothiazide, Nadolol/Bendroflumethiazide, Olmesartan/hydrochlorothiazide, Olmesartan/amlodipin/hcthiazid, Quinapril/hydrochlorothiazide, Trandolapril/verapamil hcl, triamterene/hydrochlorothiazide, Propranolol/hydrochlorothiazid Additional drug classes of interest *There were sparse events for ingrown nail claims in the outpatient cohort.eTable 4. Association of ACE inhibitor and ARB therapy on in-hospital mortality or discharge to hospice care in COVID-19 inpatient cohort. eFigure 3: Distribution of individuals in the outpatient and inpatient cohorts. (A) SARS-CoV-2 test geographic distribution: number of tests by state. Patients in 44 states were included based on a positive test. (B) COVID-19 Inpatient case distribution: number of inpatient cases by state. COVID-19 hospitalizations included in the study are represented in 47 states.Number of COVID\u221219 Tests Conducted by States of Test SitesNumber of COVID\u221219 Inpatient Cases by State of Hospitals", "latex": null, "type": "table"}}, "back_matter": []}